welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomicsBackground: Saliva, blood, tissue, and c...
-
Rectal Eversion and Double-Stapled Ileal Pouch Anal Anastomosis in Familial Adenomatous Polyposis SyndromeINTRODUCTION : Surgery is the only treat...
-
Colorectal Cancer GuidelinesThe American Society of Colon and Rectal...
-
Medication Education: F.A.P. and Medicationhttps://www.youtube.com/watch?v=UOQ94Rse...
-
Starch Powder That can be Sprinkled on Food is Tested as Cure for Bowel CancerA powder made from starch that can b...